Overview
- The peer-reviewed ACS Nano study shows perfluoropropane nanobubbles plus therapeutic ultrasound reduced tumor stiffness to about one-third after one session and kept tumors softer for at least five days.
- Pretreatment enabled roughly sixfold higher T-cell infiltration and tripled lipid nanoparticle uptake by T cells, improving intratumoral delivery.
- Investigators observed activation of immune cells within tumors and signaling that recruited additional immune cells, with related changes detected in nearby lymph nodes.
- No increased cell death or heat damage was detected in surrounding tissue during the cavitation-driven remodeling.
- The work remains preclinical in a single mouse breast cancer model, and the team cites plans for an FDA IND within about 18 months with potential early clinical trials in roughly two years.